Critical Insights From Biogen Analyst Ratings: What You Need To Know
Portfolio Pulse from Benzinga Insights
Biogen (NASDAQ:BIIB) has received mixed analyst ratings over the last three months, with 10 analysts offering diverse opinions. The average 12-month price target is $308.7, with a high of $373.00 and a low of $239.00, marking a 3.1% decrease from the previous average. Recent actions by analysts include maintaining, raising, and lowering ratings and price targets. Biogen's financials show a revenue growth rate of 0.87%, a net margin of -2.69%, an ROE of -0.47%, an ROA of -0.26%, and a debt-to-equity ratio of 0.53.
January 24, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts have mixed opinions on Biogen, with recent ratings ranging from neutral to overweight. The average price target has decreased slightly, and the company's financials show modest revenue growth but strong profitability metrics.
The mixed analyst ratings and slight decrease in the average price target suggest a neutral short-term impact on Biogen's stock price. The company's financial performance is solid, but the lower than average revenue growth rate compared to peers could temper investor enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100